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 Signaling through the Janus kinase / signal 
transducers and activators of transcription 
(JAK / STAT) pathway is important for the 
kidney ’ s response to injury and the progres-
sion of certain renal diseases. Pang  et al. 1  
(this issue) investigated the effects of 
STAT3 inhibition on the development of 
renal fibrosis in the unilateral ureteral 
obstruction (UUO) experimental model. 
Th is study confi rms the role of STAT3 acti-
vation in the development of renal fi brosis. 
However, STAT signaling mediated by 
JAK-dependent or -independent pathways 
in both renal and nonrenal cells remains 
to be elucidated in renal diseases. 
 Th e JAK / STAT pathway is a pleiotropic 
cascade essential to cytokine and growth 
hormone receptor signaling. Th e current 
model of JAK / STAT signaling holds that 
binding of cytokines or growth hormones 
to their receptor activates JAK, which in 
turn phosphorylates the intracellular 
domain of the receptor and allows the 
recruitment and phosphorylation of a 
STAT. Phosphorylated STATs form homo- 
or heterodimers, which then translocate 
into the nucleus to transactivate the 
expression of target genes. In mammals, 
the JAK family consists of four members: 
JAK1, JAK2, JAK3, and receptor tyrosine 
kinase 2. Of all the JAK / STAT pathways, 
JAK2 signaling through STAT1 and 
STAT3 is the best studied in diseases 
aff ecting the kidney ( Table 1 ). 
 Diabetic nephropathy (DN) is perhaps 
the best-described renal disorder in which 
JAK / STAT activation is important. In DN, 
angiotensin II-mediated activation of the 
JAK / STAT pathway in glomerular mesang-
ial cells has been shown to enhance the 
production of transforming growth factor-
  , collagen IV, and fi bronectin (see review, 
Marrero  et al. 2 ), which is thought to con-
tribute to the accumulation of extracellular 
matrix and glomerulosclerosis in DN. 
Although inhibition of JAK2, with AG490, 
prevents diabetic proteinuria, the eff ect of 
JAK2 inhibition on the development of 
glomerular and tubulointerstitial fi brosis 
has not been demonstrated. Berthier  et al. 
identifi ed that signaling through JAK2 is a 
highly regulated pathway in humans with 
both early and more progressive DN, using 
a transcriptomic approach with human 
complementary DNA samples obtained 
from glomerular and tubulointerstitial 
compartments. 3 When the authors per-
formed the same analysis on animal mod-
els of diabetes (db / db C57BLKS and 
streptozotocin-induced diabetic DBA / 2J 
mice), they did not fi nd enhanced JAK2 
expression in the renal cortex and glo-
meruli. 3 Th ey suggest that this diff erence 
in JAK2 expression between mice and 
humans may account for the observation 
that mice rarely progress to severe glomer-
ulosclerosis and signifi cant tubulointersti-
tial fi brosis. To specifi cally address the role 
of STAT3 activation in DN, we took 
advantage of the availability of a trans-
genic animal that has a reduced capacity 
for STAT3 activation (Stat3SA / – mice). 4 
We found that Stat3SA / – animals with 
streptozotocin (STZ) diabetes developed 
less protein uria, mesangial expansion, 
glomerular-cell proliferation, macrophage 
infi ltration, infl ammation, and abnormal 
matrix synthesis at an early stage of DN. 4 
Taken together, these studies support a 
functional role of JAK / STAT activation 
(specifi cally, JAK2 and STAT3) in the 
renal response to diabetes. 
 Activation of STAT3 has also been 
implicated in tissue fibrosis through 
increased transforming growth factor-  1 
production. Kuratsune  et al. observed a 
signifi cant increase in activated STAT3 
(Tyr705-phosphorylated STAT3 ; pSTAT3) 
in renal tubular interstitial cells of kidneys 
with UUO. 5 Th e authors speculated that 
the interstitial cells with enhanced pSTAT3 
staining in UUO kidneys are interstitial 
fi broblasts that have acquired a phenotype 
of myofi broblasts, which are regarded as 
the major eff ector cells in renal fi brosis. 
Pang  et al. 1 confi rmed the functional role 
of STAT3 activation in UUO using a spe-
cifi c STAT3 inhibitor, S3I-201. S3I-201 
abrogated the expression of   -smooth 
muscle actin and fi bronectin, which are 
markers of myofibroblasts, in cultured 
renal interstitial fi broblast cells and attenu-
ated the accumulation of extracellular 
matrix and proliferation of interstitial 
fi broblasts in UUO mice. 1 Th e number of 
infiltrating interstitial neutrophils and 
monocytes and the mRNA expression of 
proinfl ammatory cytokines (including 
tumor necrosis factor-  , interleukin-1  , 
intercellular adhesion molecule-1, and 
monocyte chemoattractant protein-1) in 
the obstructed kidney were reduced to the 
basal level by S3I-201. On the basis of these 
observations, the authors concluded that 
STAT3 mediates kidney fi brosis through 
suppression of renal interstitial fi broblast 
activation and inhibition of leukocyte 
infi ltration and proinfl ammatory cytokine 
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expression. Th is study adds to our under-
standing of the important role that STAT3 
plays in the development of obstruction-
induced renal fi brosis. However, the pri-
mary cell or cells in which STAT3 activation 
is important for renal fi brosis remain to be 
determined. Is it the activation of STAT3 
in interstitial fibroblasts that facilitates 
the proliferation and transitioning to a 
myofi broblast phenotype, or is it the acti-
vation of STAT3 in infi ltrating mononu-
clear cells that increases proinfl ammatory 
and profi brotic cytokine production and 
stimulates myofi broblast proliferation — or 
is it a combination of both? Future studies 
should be directed at identifying the role 
of STAT3 in the key eff ector cells of renal 
fi brosis. Furthermore, we need to be cau-
tious when extending findings derived 
from the UUO model to renal fi brosis in 
chronic renal diseases where tubular dam-
age is not the primary cause of injury. 
UUO is a well-described experimental 
model of renal fi brosis. However, tubular 
interstitial fibrosis in diseases where 
glomerular injury is the primary cause of 
renal dysfunction, such as advanced 
DN or chronic glomerulonephritis, is 
likely to have a diff erent disease process 
as compared with UUO. 
 In addition to DN and renal fi brosis, 
activation of JAK / STAT pathways ( Figure 
1 ) has also been described in adriamy-
cin-induced experimental nephrotic syn-
drome, 6 ischemia / reperfusion injury, 7 
and HgCl 2 -induced acute kidney injury 
(AKI). 8 In adriamycin-treated mice, 
AG490 treatment reduced the infi ltration 
of macrophages and T lymphocytes and 
improved proteinuria and renal failure; 6 
and in ischemia / reperfusion injury, 
AG490 improved renal function and 
histological lesions and reduced macro-
phage accumulation. 7 However, as 
STAT1, STAT3, and STAT5 are all known 
downstream eff ectors of JAK2, it is not 
possible to determine which STAT is the 
key mediator of JAK2 signaling in these 
two experimental models. In HgCl 2 -
induced AKI, there is an increase in the 
expression of interleukin-6 (IL-6) 
and pSTAT3 staining in the renal tubular 
epithelium. 8 STAT3 phosphorylation is 
enhanced by the complex of IL-6 and 
soluble IL-6 receptor (sIL-6R) instead of 
the classic pathway of IL-6 binding to the 
gp130 receptor. Mice treated with a 
fusion protein of IL-6 / sIL-6R are resistant 
to AKI. 8 Nechemia-Arbely  et al. specu-
late that STAT3 activation in IL-6 / sIL-
6R-treated animals transactivates the 
expression of a negative regulator of 
gp130 signaling, suppressor of cytokine 
signaling proteins 3 (SOCS3), and redox-
related genes to protect against oxidative 
stress and reduce renal injury. Th e func-
tional role of STAT3 activation in AKI 
remains to be determined. 
 STAT3 activation through JAK2-inde-
pendent pathways has been described in 
anti-Thy1.1 glomerulonephritis 9 and 
podocyte proliferation in HIV-associated 
nephropathy. 10 In the anti-Th y1.1 glomer-
ulonephritis model, STAT3 activation is 
mediated by the binding of growth arrest-
specifi c gene 6, an endogenous mitogen 
that enhances mesangial-cell proliferation, 
to a receptor tyrosine kinase 2, Axl. In 
 Table 1  |  Activation of JAK / STAT pathway in renal and nonrenal cells of kidney diseases 
                                                        Renal cells  Nonrenal cells 




 Tubular epithelial 
cells  Macrophages 
 Lymphocytes 
and neutrophils 
 DN  STAT3 activation in glomeruli of STZ 
diabetic rats 4 
    
  Ang II / AT 1 
activates JAK2 /
 STAT1 and STAT3 
in mesangial cells 2 
     
  JAK2 activation in glomerular and tubulointerstitial compartments of humans with DN 3   
 Renal fi brosis / UUO    STAT3 activation in 
tubulointerstitial 
cells / myofi broblasts 
and tubular 
epithelial cells of 
UUO kidney 1,5 




of UUO kidney 1 
 
 HIVAN   Src-dependent 
STAT3 activation in 
podocytes 10 
    
 HgCl 2 -induced 
acute kidney injury 
    pSTAT3 predomi-
nantly in tubular 




 pSTAT3 in 
mesangial cells 9 
     
 I / R injury and 
adriamycin-induced 
nephropathy 
 pJAK2, pSTAT1, and pSTAT3 are increased in the kidney, but localization of JAK / STAT activation was not performed 6,7 
 Abbreviations: Ang II, angiotensin II; AT 1 , angiotensin 1 receptor; DN, diabetic nephropathy; HIVAN, HIV-associated nephropathy; I / R, ischemia / reperfusion; p, phosphorylated; 
STZ, streptozotocin; UUO, unilateral ureteral obstruction. 
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HIV-infected podocytes, activation of 
STAT3 by an HIV protein, Nef, promotes 
the phosphorylation of STAT3 through an 
Src-dependent mechanism and contrib-
utes to the proliferation of podocytes. 10 
 None of the studies above have ade-
quately addressed whether it is the activa-
tion of STAT3 in renal cells (for example, 
renal tubular epithelial cells, podocytes, 
mesangial cells, and interstitial fibro-
blasts) or infiltrating leukocytes and 
macrophages that contribute to the 
pathogenesis of renal fi brosis, DN, and 
glomerulosclerosis. Although JAK / STAT 
signaling is mechanistically simple with 
only a few components, more than 40 
cytokine receptors signal through combi-
nations of four JAK and seven STAT fam-
ily members. It is known that many 
receptors signal through a small number 
of JAKs and that diff erent cells and tissues 
express distinct receptor combinations 
that respond to cytokine combinations 
that are specifi c to the cellular context. 
Th e complexity of the system is further 
compounded by a layer of negative 
regulators of the pathway mediated by 
suppressor of cytokine signaling proteins, 
protein inhibitors of activated STATs, and 
protein tyrosine phosphatases. This is 
an area of JAK / STAT signaling in renal 
disease that has not been explored. 
 In summary, activation of the JAK / STAT 
pathway is involved in several experimen-
tal models and human renal diseases. Spe-
cifi cally, DN and renal fi brosis from UUO 
have the most evidence to support a func-
tional role of JAK / STAT activation. Tar-
geted knockout of STAT3 in diff erent cell 
types will need to be carried out to spe-
cifi cally identify the cells (renal versus 
nonrenal, glomerular versus tubular) in 
which JAK / STAT activation is important. 
Furthermore, it remains to be deter-
mined whether JAK-independent activa-
tion of STATs might play a role in renal 
disease other than podocyte proliferation 
of HIV-associated nephropathy. The 
potential for using specific inhibitors 
of STAT3 or JAK2 for treatment of 
renal fibrosis and DN will need to be 
further evaluated in the future. 
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 Figure 1  |  Activation of JAK / STAT pathway in renal and nonrenal cells of kidney diseases. In diabetic nephropathy (DN), angiotensin II (Ang II) binding 
to angiotensin 1 receptor (AT 1 ) activates JAK2 / STAT1 and STAT3 in mesangial cells. In the unilateral ureteral obstruction (UUO) model of renal fibrosis, STAT3 
activation has been observed in tubulointerstitial cells, which are thought to be myofibroblasts, as well as tubular epithelial cells and macrophages. In 
HIV-associated nephropathy (HIVAN),  nef -induced podocyte proliferation occurs through Src-dependent STAT3 activation. In HgCl 2 -induced acute kidney 
injury and anti-Thy1.1 glomerulonephritis (Thy1.1 GN), STAT3 is activated in tubular epithelial cells and mesangial cells, respectively. 
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 A race for RAGE ligands 
 Erwin D.  Schleicher 1 
 In experimental animals a causal involvement of the multiligand 
receptor for advanced glycation end products (RAGE) in the 
development of diabetic vascular complications has been 
demonstrated. However, the nature of RAGE ligands present in patients 
with diabetic nephropathy has not yet been defined; this leaves open 
the relevance of the RAGE system to the human disease. 
 Kidney International (2010)  78, 234 – 236.  doi: 10.1038/ki.2010.146 
 Th e glycated hemoglobin HbA1c is now 
widely accepted for assessment of the meta-
bolic control of diabetic patients. Since 
large epidemiological studies (the Diabetes 
Control and Complications Trial and the 
UK Prospective Diabetes Study) clearly 
indicate that diabetic microvascular, par-
ticularly retinal and renal, complications 
are associated with glycemic control 
assessed by HbA1c, therapeutic goals have 
been introduced in the respective guide-
lines. The importance of blood glucose 
levels for the development of late diabetic 
complications has long been known and 
implies that chronically elevated glucose 
levels are deleterious to the vascular sys-
tem. Several fi ndings argue against a direct 
toxic eff ect of increased glucose concentra-
tions: (1) blood with the same degree of 
hyperglycemia is circulating through all 
organs and tissues of a given diabetic 
patient, but the kidneys, retinas, or nerves 
are diff erently aff ected intra- and interin-
dividually; (2) while some patients with 
poor metabolic control, that is, substantial 
hyperglycemia, have few, if any, microvas-
cular complications, other patients with 
appropriate metabolic control experience 
fast and widespread microvascular lesions; 
(3) aff ected tissues appear to have a  ‘ glyc-
emic memory ’ ; and (4) in nondiabetic sub-
jects, HbA1c is more strongly associated with 
risks of cardiovascular disease and death 
from any cause as compared with fasting 
glucose. 1 Furthermore, the animal kingdom 
teaches us that lifelong glucose levels above 
200  mg / dl, for example in birds, are not neces-
sarily accompanied by microvascular 
lesions — even in long-lived parrots. Together 
these arguments indicate that elevated glu-
cose  per se may not be the toxic agent causing 
the diabetes-specifi c vascular lesions. 
 Th e fi nding that not only HbA1c but also 
other proteins in the human body are sub-
ject to glycation has raised the possibility 
that hyperglycemia via glycation of proteins 
may cause the deleterious eff ects in poorly 
controlled diabetic patients. Indeed, in dia-
betic subjects, elevated glycation was found 
in long-lived, particularly extracellular, pro-
teins of aff ected organs and tissues such as 
glomeruli, nerves, and aortas, and also in 
lungs and tendons. Vlassara  et al. 2 recog-
nized that glycated proteins are not stable 
over time and thus form advanced glycation 
end products (AGEs), a still poorly defi ned, 
heterogeneous group of protein modifi ca-
tions. Meanwhile, the oxidative formation 
of  N -carboxymethyl-lysine (CML) from 
protein-bound glycated lysines has been 
shown to be a major AGE in vascular lesions 
that is increased in diabetic patients. 3 
 However, the presence of AGE did not 
explain the pathogenesis of hyperglyc-
emia-induced vascular lesions. A major 
step forward was the identification of 
a cell-surface receptor for AGEs (RAGE) 
by Neeper  et al. 4 Later on, a soluble 
form of RAGE (sRAGE) was found in 
plasma of experimental animals and dia-
betic patients. Subsequent characteriza-
tion revealed RAGE as a multiligand 
pattern recognition receptor of the immu-
noglobulin superfamily. RAGE does not 
promote the uptake and removal of lig-
ands, but the RAGE – ligand interaction 
induces a proinfl ammatory and proco-
agulant state. Ligand engagement of 
RAGE activates the nuclear factor-  B 
(NF-  B) and Egr-1 signaling pathways, 
both involved in acute cellular stress 
responses. Activation of these pathways, 
which includes the stimulation of reactive 
oxygen species, leads to enhanced expres-
sion of proinfl ammatory cytokines such 
as interleukins and tumor necrosis factor. 
Prolonged activation of RAGE results in 
sustained activation of NF-  B through  de 
novo synthesis of RelA / p65, generating an 
increasing pool of transcriptionally active 
NF-  B, which can counteract the negative 
autoregulatory loops. By this mechanism, 
RAGE represents a master switch convert-
ing a transient proinfl ammatory response 
into a sustained cellular dysfunction. 5 
 Although fi rst characterized as a recep-
tor for AGEs, subsequent characterization 
of endogenous binding partners showed 
that RAGE also transduces signals by pro-
teins that are secreted or released from 
cells activated by infl ammatory stimuli. 5 
Collectively, these molecules warn the 
tissue of acute danger and have therefore 
been called danger-associated molecular 
patterns (DAMPs). These endogenous 
binding partners include high-mobility 
group box 1 (HMGB1), members of the 
S100 / calgranulin family,   2 -integrin Mac, 
amyloid-  peptide, and   -sheet fi brils. 
S100 / calgranulins are a family of small 
Ca-binding proteins with a molecular 
weight of approximately 10.5  kDa that 
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